Cargando…
HIV evolution and diversity in ART-treated patients
Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity pr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789667/ https://www.ncbi.nlm.nih.gov/pubmed/29378595 http://dx.doi.org/10.1186/s12977-018-0395-4 |
_version_ | 1783296328974991360 |
---|---|
author | van Zyl, Gert Bale, Michael J. Kearney, Mary F. |
author_facet | van Zyl, Gert Bale, Michael J. Kearney, Mary F. |
author_sort | van Zyl, Gert |
collection | PubMed |
description | Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity prior to ART and how it is affected by suppressive ART, the debate on viral replication and evolution in the presence of ART, HIV compartmentalization across various tissues, and mechanisms for the emergence of drug resistance. It also describes how CD4+ T cells that were likely infected with latent proviruses prior to initiating treatment can proliferate before and during ART, providing a renewable source of infected cells despite therapy. Some expanded cell clones carry intact and replication-competent proviruses with a small fraction of the clonal siblings being transcriptionally active and a source for residual viremia on ART. Such cells may also be the source for viral rebound after interrupting ART. The identical viral sequences observed for many years in both the plasma and infected cells of patients on long-term ART are likely due to the proliferation of infected cells both prior to and during treatment. Studies on HIV diversity may reveal targets that can be exploited in efforts to eradicate or control the infection without ART. |
format | Online Article Text |
id | pubmed-5789667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57896672018-02-08 HIV evolution and diversity in ART-treated patients van Zyl, Gert Bale, Michael J. Kearney, Mary F. Retrovirology Review Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity prior to ART and how it is affected by suppressive ART, the debate on viral replication and evolution in the presence of ART, HIV compartmentalization across various tissues, and mechanisms for the emergence of drug resistance. It also describes how CD4+ T cells that were likely infected with latent proviruses prior to initiating treatment can proliferate before and during ART, providing a renewable source of infected cells despite therapy. Some expanded cell clones carry intact and replication-competent proviruses with a small fraction of the clonal siblings being transcriptionally active and a source for residual viremia on ART. Such cells may also be the source for viral rebound after interrupting ART. The identical viral sequences observed for many years in both the plasma and infected cells of patients on long-term ART are likely due to the proliferation of infected cells both prior to and during treatment. Studies on HIV diversity may reveal targets that can be exploited in efforts to eradicate or control the infection without ART. BioMed Central 2018-01-30 /pmc/articles/PMC5789667/ /pubmed/29378595 http://dx.doi.org/10.1186/s12977-018-0395-4 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review van Zyl, Gert Bale, Michael J. Kearney, Mary F. HIV evolution and diversity in ART-treated patients |
title | HIV evolution and diversity in ART-treated patients |
title_full | HIV evolution and diversity in ART-treated patients |
title_fullStr | HIV evolution and diversity in ART-treated patients |
title_full_unstemmed | HIV evolution and diversity in ART-treated patients |
title_short | HIV evolution and diversity in ART-treated patients |
title_sort | hiv evolution and diversity in art-treated patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789667/ https://www.ncbi.nlm.nih.gov/pubmed/29378595 http://dx.doi.org/10.1186/s12977-018-0395-4 |
work_keys_str_mv | AT vanzylgert hivevolutionanddiversityinarttreatedpatients AT balemichaelj hivevolutionanddiversityinarttreatedpatients AT kearneymaryf hivevolutionanddiversityinarttreatedpatients |